Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Allogeneic Vaccine Modified to Express HLA A2/4-1BB Ligand for High Risk or Low Residual Disease Melanoma Patients

NCT01861938 is registered in ClinicalTrials.gov with Hadassah Medical Organization as lead sponsor.

NCT NCT01861938
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01861938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Allogeneic Vaccine Modified to Express HLA A2/4-1BB Ligand for High Risk or Low Residual Disease Melanoma Patients
Lead sponsor
Hadassah Medical Organization
Phase
Phase 2/3
Overall status
Withdrawn
Start date
March 31, 2017
Completion date
March 31, 2019
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

high risk hla-a2+ melanoma, metastatic disease